Clinical Trial Update: Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia [Phase 3]

View source ↗

Summary

Phase 3 trial in Saudi Arabia evaluated immunogenicity and safety of the Menactra meningococcal vaccine in adolescents; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Neisseria Meningitidis, Meningococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2011-03-04